Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a maj...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2008
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727882/ |